Identification of Group B Streptococcal Sip Protein, Which Elicits Cross-protective Immunity

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 2000 Sep 19

PMID 10992461

Citations 62

Authors

B R Brodeur

M Boyer

I Charlebois

J Hamel

F Couture

C R Rioux

D Martin

Affiliations

Soon will be listed here.

Abstract

A protein of group B streptococci (GBS), named Sip for surface immunogenic protein, which is distinct from previously described surface proteins, was identified after immunological screening of a genomic library. Immunoblots using a Sip-specific monoclonal antibody indicated that a protein band with an approximate molecular mass of 53 kDa which did not vary in size was present in every GBS strain tested. Representatives of all nine GBS serotypes were included in the panel of strains. Cloning and sequencing of the sip gene revealed an open reading frame of 1,305 nucleotides coding for a polypeptide of 434 amino acid residues, with a calculated pI of 6. 84 and molecular mass of 45.5 kDa. Comparison of the nucleotide sequences from six different strains confirmed with 98% identity that the sip gene is highly conserved among GBS isolates. N-terminal amino acid sequencing also indicated the presence of a 25-amino-acid signal peptide which is cleaved in the mature protein. More importantly, immunization with the recombinant Sip protein efficiently protected CD-1 mice against deadly challenges with six GBS strains of serotypes Ia/c, Ib, II/R, III, V, and VI. The data presented in this study suggest that this highly conserved protein induces cross-protective immunity against GBS infections and emphasize its potential as a universal vaccine candidate.

Citing Articles

A CRISPRi Library Screen in Group B Identifies Surface Immunogenic Protein (Sip) as a Mediator of Multiple Host Interactions.

Firestone K, Gopalakrishna K, Rogers L, Peters A, Gaddy J, Nichols C bioRxiv. 2024; .

PMID: 39677656 PMC: 11643019. DOI: 10.1101/2024.12.06.627252.

Surface protein distribution in Group B Streptococcus isolates from South Africa and identifying vaccine targets through in silico analysis.

Gent V, Lu Y, Lukhele S, Dhar N, Dangor Z, Hosken N Sci Rep. 2024; 14(1):22665.

PMID: 39349584 PMC: 11442663. DOI: 10.1038/s41598-024-73175-4.

Using Surface Immunogenic Protein as a Carrier Protein to Elicit Protective Antibody to Multiple Serotypes for Candidate Group B Streptococcal Glycan Conjugate Vaccines.

Duan H, Huang W, Lv Q, Liu P, Li Q, Kong D Vaccines (Basel). 2024; 12(6).

PMID: 38932301 PMC: 11209137. DOI: 10.3390/vaccines12060573.

Exploring the Immunoprotective Potential of a Nanocarrier Immersion Vaccine Encoding Sip against Infection in Tilapia ().

Cao Y, Liu J, Liu G, Du H, Liu T, Wang G Vaccines (Basel). 2023; 11(7).

PMID: 37515077 PMC: 10383804. DOI: 10.3390/vaccines11071262.

Ultra-Fast Impedimetric Immunoassay for Detection of Using Carbon Electrode with Nanodiamonds Film.

Bigus D, Lewandowska W, Biega E, Grela A, Siedlar A, Sosnowska M Micromachines (Basel). 2023; 14(5).

PMID: 37241699 PMC: 10222630. DOI: 10.3390/mi14051076.

References

Larsson C, Stalhammar-Carlemalm M, Lindahl G . Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. Vaccine. 1999; 17(5):454-8. DOI: 10.1016/s0264-410x(98)00218-7. View

Johnson D, Ferrieri P . Group B streptococcal Ibc protein antigen: distribution of two determinants in wild-type strains of common serotypes. J Clin Microbiol. 1984; 19(4):506-10. PMC: 271105. DOI: 10.1128/jcm.19.4.506-510.1984. View

Kling D, Gravekamp C, Madoff L, Michel J . Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus. Infect Immun. 1997; 65(4):1462-7. PMC: 175154. DOI: 10.1128/iai.65.4.1462-1467.1997. View

Briles D, King J, Gray M, McDaniel L, Swiatlo E, Benton K . PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine. 1996; 14(9):858-67. DOI: 10.1016/0264-410x(96)82948-3. View

Wessels M, Paoletti L, PINEL J, Kasper D . Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Infect Dis. 1995; 171(4):879-84. DOI: 10.1093/infdis/171.4.879. View

Lancefield R, McCarty M, Everly W . Multiple mouse-protective antibodies directed against group B streptococci. Special reference to antibodies effective against protein antigens. J Exp Med. 1975; 142(1):165-79. PMC: 2189884. DOI: 10.1084/jem.142.1.165. View

Walters D, Stirewalt V, Melville S . Cloning, sequence, and transcriptional regulation of the operon encoding a putative N-acetylmannosamine-6-phosphate epimerase (nanE) and sialic acid lyase (nanA) in Clostridium perfringens. J Bacteriol. 1999; 181(15):4526-32. PMC: 103582. DOI: 10.1128/JB.181.15.4526-4532.1999. View

Simmonds R, Simpson W, Tagg J . Cloning and sequence analysis of zooA, a Streptococcus zooepidemicus gene encoding a bacteriocin-like inhibitory substance having a domain structure similar to that of lysostaphin. Gene. 1997; 189(2):255-61. DOI: 10.1016/s0378-1119(96)00859-1. View

Larsson C, Stalhammar-Carlemalm M, Lindahl G . Experimental vaccination against group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins Rib and alpha. Infect Immun. 1996; 64(9):3518-23. PMC: 174257. DOI: 10.1128/iai.64.9.3518-3523.1996. View

10.

WILKINSON H, Eagon R . Type-specific antigens of group B type Ic streptococci. Infect Immun. 1971; 4(5):596-604. PMC: 416359. DOI: 10.1128/iai.4.5.596-604.1971. View

11.

Harrison L, Elliott J, Dwyer D, Libonati J, Ferrieri P, Billmann L . Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis. 1998; 177(4):998-1002. DOI: 10.1086/515260. View

12.

Baltimore R, Baker C, Kasper D . Antibody to group B Streptococcus type III in human sera measured by a mouse protection test. Infect Immun. 1981; 32(1):56-61. PMC: 350586. DOI: 10.1128/iai.32.1.56-61.1981. View

13.

Plante M, Cadieux N, Rioux C, Hamel J, Brodeur B, Martin D . Antigenic and molecular conservation of the gonococcal NspA protein. Infect Immun. 1999; 67(6):2855-61. PMC: 96592. DOI: 10.1128/IAI.67.6.2855-2861.1999. View

14.

Baker C, Kasper D . Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976; 294(14):753-6. DOI: 10.1056/NEJM197604012941404. View

15.

Lachenauer C, Kasper D, Shimada J, Ichiman Y, Ohtsuka H, Kaku M . Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. J Infect Dis. 1999; 179(4):1030-3. DOI: 10.1086/314666. View

16.

Wastfelt M, Stalhammar-Carlemalm M, Delisse A, Cabezon T, Lindahl G . Identification of a family of streptococcal surface proteins with extremely repetitive structure. J Biol Chem. 1996; 271(31):18892-7. DOI: 10.1074/jbc.271.31.18892. View

17.

Areschoug T, Stalhammar-Carlemalm M, Larsson C, Lindahl G . Group B streptococcal surface proteins as targets for protective antibodies: identification of two novel proteins in strains of serotype V. Infect Immun. 1999; 67(12):6350-7. PMC: 97041. DOI: 10.1128/IAI.67.12.6350-6357.1999. View

18.

Kvam A, Bevanger L, Loseth K . An apparently new strain-variable Streptococcus agalactiae protein. Adv Exp Med Biol. 1997; 418:355-7. DOI: 10.1007/978-1-4899-1825-3_85. View

19.

Michel J, Madoff L, Olson K, Kling D, Kasper D, Ausubel F . Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B streptococci. Proc Natl Acad Sci U S A. 1992; 89(21):10060-4. PMC: 50277. DOI: 10.1073/pnas.89.21.10060. View

20.

Lin F, Clemens J, Azimi P, Regan J, Weisman L, Philips 3rd J . Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. J Infect Dis. 1998; 177(3):790-2. DOI: 10.1086/517810. View